

GenomeDx: Whole-Genome Chromosomal Microarray Comparative Genomic Hybridization (CGH) and Single Nucleotide Polymorphism (SNP) Array for Copy Number and Uniparental Disomy (UPD) Analysis

Routine chromosomal analysis for constitutional developmental disorders has shifted from G-banded karyotype analysis to DNA chromosomal microarray (CMA) as a first-tier test.¹ The clinical sensitivity of CMA in patients with developmental delay, intellectual disability, and/or congenital anomalies is at least 10% higher than that associated with karyotyping and subtelomere FISH. CMA can detect pathogenic copy number variation (CNV) in up to 15% of individuals with intellectual disability and developmental delay when a karyotype is normal.^{3,4,5} In addition, 7% of individuals with non-syndromic autism and as many as 27% of individuals with autism spectrum disorders and additional congenital anomalies carry pathogenic CNVs detectable by CMA.^{6,7,8} A variety of CNVs are also reported to cause epilepsy.⁹ The addition of probes containing single nucleotide polymorphisms (SNP) to a microarray allows for the detection of long stretches of homozygosity, which may result from uniparental disomy (UPD). While relatively rare, some cases of uniparental disomy are relevant to disorders of imprinting as well as to recessive disorders caused by inheritance of a variant within a long stretch of homozygosity.^{10,11}

Test Indications:

- (1) Primary screening test for diagnosis of persons with dysmorphic features, birth defects, intellectual disability/developmental delay, autism spectrum disorder, multiple congenital anomalies, seizures or any suspicion of chromosomal imbalance.
- (2) Suspected whole-chromosome or segmental UPD related to an imprinting disorder or to a recessive disorder (with detection of a homozygous variant in a proband who has only one carrier parent and non-paternity is ruled out).
- (3) Determine breakpoints of chromosomal rearrangements previously detected by conventional cytogenetic methods or technologies that do not provide genome-wide coverage.

Test Method and Sensitivity:

The GenomeDx v5 (whole-genome chromosomal array) contains 118,000 oligonucleotide probes used for detection of copy number variants (CNVs). For blood specimens, deletions >250 kb and duplications >500 kb will be reported. For oral rinse/buccal specimens, deletions >300 kb and duplications >1 Mb are reported. Smaller events may be reported in certain clinically relevant regions. In addition, this CMA contains 66,000 SNP probes throughout the genome and can detect stretches of homozygosity extending 5 Mb or longer. Interpretation of

results sometimes depends on whether a CNV is inherited or de novo, and analysis of parental samples is useful for accurate interpretation.

Limitations:

CMA cannot detect balanced chromosomal rearrangements (inversions, balanced insertions, and reciprocal translocations), genomic alterations in regions that are not represented on the microarray, polyploidy, aberrations in repeat sequences (e.g., short arms of acrocentric chromosomes and heterochromatic regions), and variants of single or small stretches of nucleotides (point variants, indels, etc). CMA cannot detect low-level mosaicism (<20%) on blood specimens or mosaicism of any level on an oral rinse or buccal sample. CMA cannot identify pure uniparental heterodisomy (i.e., can only identify uniparental isodisomy or segmental UPD). With GenomeDx v5, regions of homozygosity (ROH) will be reported if there is at least one region ≥ 10 Mb, or two regions each ≥ 8 Mb, suggesting identity by descent. The possibility of uniparental disomy (UPD) is reported when there is an isolated terminal ROH ≥ 10 Mb or interstitial ROH ≥ 20 Mb. A normal finding at a specific locus does not rule out the diagnosis of a genetic disorder associated with that locus since another abnormality may be present but undetectable by this chromosomal microarray design.

Parental Testing Policy:

GeneDx recommends parental testing to evaluate the inheritance of an abnormality (familial or de novo) and also to clarify the clinical significance of copy number changes. GeneDx uses FISH, MLPA, quantitative PCR (qPCR), or targeted CMA, as appropriate, for parental analysis. For clinically well-characterized genomic imbalances, parental analysis is available as a separate test for an additional cost (see Known Familial Deletion/Duplication testing). For genomic imbalances of unclear significance, GeneDx offers free parental analysis if clinical information on the parents is provided.

References:

1. Miller D et al., (2010) *Am J Hum Genet* 86(5): 749-764.
2. Kearney H et al., (2011) *Genet Med* 13:680-685
3. Fan YS et al., (2007) *Hum Mut* 28:1124-1132.
4. McMullan, DJ et al., (2009) *Hum Mutat* 30:1082-1092.
5. Aradhya S et al., (2007) *Am J Med Genet* 143A:1431-1441.
6. Sanders SJ et al., (2011) *Neuron* 70:863-885.
7. Bremer A et al., (2010) *Am J Med Genet B Neuropsychiatr Genet* 156(2):115-24.
8. Marshall CR et al., (2008) *Am J Hum Genet* 82:477-488.
9. Mullery JC and Mefford HC. *Epilepsia* 52:423-432, 2011.
10. Yamazawa, K et al., (2010) *Am J Med Genet* 154C: 329-334.
11. Engel E. *Eur J Hum Genet* (2006) 14, 1158–116